SCHEMBL8720904

SCHEMBL8720904

CCCCOC(=O)CCCC(=O)Nc1ccc2scc(C3=CCN4CCCCC4CC3)c2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.37
ALDH1A1 P00352 4/20 0.36
MAPT P10636 4/20 0.36
KDM4E B2RXH2 1/20 0.36
HTT P42858 1/20 0.35
ADRB2 P07550 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
GAA P10253 1/20 0.33
KMT2A Q03164 4/20 0.33
MEN1 O00255 2/20 0.33
TERT O14746 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
MAPK1 P28482 1/20 0.33
LMNA P02545 1/20 0.32
HTR1D P28221 1/20 0.32
HTR1B P28222 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8724068 0.89 KDM4E (0.43) ALDH1A1MAPTKDM4EHTTHPGD
SCHEMBL8723649 0.89 MCHR1 (0.36) ALDH1A1MAPTKDM4EHPGDSMN1; SMN2
SCHEMBL8725984 0.83 NPC1 (0.39) EPHX2ALDH1A1MAPTSMN1; SMN2MAPK1
SCHEMBL8723878 0.81 NR1H4 (0.46) MAPTKDM4EHTTADRB2L3MBTL1
SCHEMBL8724051 0.80 AKR1C3 (0.38) MAPTHTTSMN1; SMN2HRH3CYP2D6
SCHEMBL8721780 0.80 HCRTR1 (0.39) MAPTADRB2SMN1; SMN2KMT2AHRH3
SCHEMBL30909135 0.80 HCRTR1 (0.39) MAPTADRB2SMN1; SMN2KMT2AHRH3
SCHEMBL8720693 0.79 NPC1 (0.44) ALDH1A1MAPTADRB2SMN1; SMN2GAA
SCHEMBL8723706 0.77 MLNR (0.36) ALDH1A1HTTHPGDKMT2AMEN1
SCHEMBL8720752 0.77 MEN1 (0.38) ALDH1A1MAPTKDM4EHTTADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
WO-2024073845-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ, LIMITED PARTNERSHIP (CA) 2024-04-11 WO disclosed
EP-0875513-A1 Substituted heteroaromatic 5-HT 1F agonists ELI LILLY AND COMPANY (US) 1998-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D EPHX2 2998/4885ALDH1A1 563/4885MAPT 3544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.